<i>Ginkgo biloba</i> extract EGb 761®, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: A randomised, double-blind, exploratory trial

Yancheva, S.; Ihl, Ralf; Nikolova, Gergana; Panayotov, Plamen; Schlaefke, Sandra; Hoerr, Robert

doi:10.1080/13607860902749057

Cited by 109 publications

(55 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eight studies were placebo controlled, while two studies were a head-to-head trial with donepezil as comparison group [50] or a triple-blind study with Gb, donepezil, and placebo [51]. The very different dosages of Gb and donepezil rendered meta-analytical examination unfeasible in the latter studies.…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review and Meta-Analysis ofGinkgo bilobain Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine

Brondino

Silvestri

et al. 2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Ginkgo biloba (Gb) has demonstrated antioxidant and vasoactive properties as well as clinical benefits in several conditions such as ischemia, epilepsy, and peripheral nerve damage. Additionally, Gb is supposed to act as potential cognitive enhancer in dementia. So far, several trials have been conducted to investigate the potential effectiveness of Gb in neuropsychiatric conditions. However, the results of these studies remain controversial. We conducted a systematic review and a meta-analysis of three randomised controlled trials in patients with schizophrenia and eight randomised controlled trials in patients with dementia. Gb treatment reduced positive symptoms in patients with schizophrenia and improved cognitive function and activities of daily living in patients with dementia. No effect of Gb on negative symptoms in schizophrenic patients was found. The general lack of evidence prevents drawing conclusions regarding Gb effectiveness in other neuropsychiatric conditions (i.e., autism, depression, anxiety, attention-deficit hyperactivity disorder, and addiction). Our data support the use of Gb in patients with dementia and as an adjunctive therapy in schizophrenic patients.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Review and Meta-Analysis ofGinkgo bilobain Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine

Brondino

Silvestri

et al. 2013

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Therefore, additional approaches are needed, and should include drugs that target various components of the neurodegeneration cascade. For example, there is evidence suggesting that the combined administration of a acetylcholinesterase inhibitors and anti-oxidants (Formula F or Ginkgo biloba-EGb 761) can more effectively improve cognitive performance than either compound alone [261, 262]. Since NMDA can promote insulin resistance [263], and NMDA neurotoxicity can be attenuated or prevented by insulin stimulation [264].…”

Section: Mechanisms Of Brain Insulin/igf Resistance In Neurodegeneratmentioning

confidence: 99%

Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease

Monte

2012

CAR

376

219

View full text Add to dashboard Cite

Alzheimer's disease [AD] is the most common cause of dementia in North America. Despite 30+ years of intense investigation, the field lacks consensus regarding the etiology and pathogenesis of sporadic AD, and therefore we still do not know the best strategies for treating and preventing this debilitating and costly disease. However, growing evidence supports the concept that AD is fundamentally a metabolic disease with substantial and progressive derangements in brain glucose utilization and responsiveness to insulin and insulin-like growth factor [IGF] stimulation. Moreover, AD is now recognized to be heterogeneous in nature, and not solely the end-product of aberrantly processed, misfolded, and aggregated oligomeric amyloid-beta peptides and hyperphosphorylated tau. Other factors, including impairments in energy metabolism, increased oxidative stress, inflammation, insulin and IGF resistance, and insulin/IGF deficiency in the brain should be incorporated into all equations used to develop diagnostic and therapeutic approaches to AD. Herein, the contributions of impaired insulin and IGF signaling to AD-associated neuronal loss, synaptic disconnection, tau hyperphosphorylation, amyloid-beta accumulation, and impaired energy metabolism are reviewed. In addition, we discuss current therapeutic strategies and suggest additional approaches based on the hypothesis that AD is principally a metabolic disease similar to diabetes mellitus. Ultimately, our ability to effectively detect, monitor, treat, and prevent AD will require more efficient, accurate and integrative diagnostic tools that utilize clinical, neuroimaging, biochemical, and molecular biomarker data. Finally, it is imperative that future therapeutic strategies for AD abandon the concept of uni-modal therapy in favor of multi-modal treatments that target distinct impairments at different levels within the brain insulin/IGF signaling cascades.

show abstract

“…Another recent study found that Ginkgo biloba was beneficial on scores of neuropsychiatric impairment, including apathy and depression/dysphoria, compared to placebo in a sample of adults with dementia [22]. An additional study showed some improvement in ratings of depression and cognition after taking Ginkgo biloba in a sample of adults who had Alzheimer's [23]. Thus, our findings appear to support other research that Max Stress B, similar to other nutrients, has the ability to improve subjective ratings of mental health.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Methylated Vitamin B Complex on Depressive and Anxiety Symptoms and Quality of Life in Adults with Depression

et al. 2013

View full text Add to dashboard Cite

Depression, the most common type of mental illness, is the second leading cause of disability and is increasing among Americans. The effect of improved nutrition, particularly with dietary supplements, on depression may provide an alternative to standard medical treatment. Some studies have shown that certain nutrients (e.g., inositol and S-adenosyl methionine) are effective at improving depressed mood, although the results are not unequivocal. The current study was a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of a vitamin B complex nutritional supplement (Max Stress B) for improving depressive and anxiety symptoms according to the Beck Depression and Anxiety Inventories (BDI and BAI) in 60 adults diagnosed with major depression or other forms of depressive disorders. Secondary outcomes included quality of life according to the SF-36. Participants were assessed at baseline and 30- and 60-day followups. Max Stress B showed significant and more continuous improvements in depressive and anxiety symptoms, compared to placebo. Additionally, Max Stress B showed significant improvement on the mental health scale of the SF-36 compared to placebo. Thus, we showed modest utility of Max Stress B to improve mood symptoms and mental health quality of life in adults with depression.

show abstract

Ginkgo biloba extract EGb 761®, donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: A randomised, double-blind, exploratory trial

Cited by 109 publications

References 26 publications

A Systematic Review and Meta-Analysis ofGinkgo bilobain Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine

A Systematic Review and Meta-Analysis ofGinkgo bilobain Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine

Brain Insulin Resistance and Deficiency as Therapeutic Targets in Alzheimers Disease

The Effect of Methylated Vitamin B Complex on Depressive and Anxiety Symptoms and Quality of Life in Adults with Depression

Contact Info

Product

Resources

About